Management Team


Pablo L.

Pablo Legorreta

Founder and Chief Executive Officer

Mr. Legorreta has over 20 years of experience investing in pharmaceutical royalties, and building and managing a rapidly growing life sciences investment company that is today one of the largest dedicated life sciences investors in the world. Prior to founding Royalty Pharma in 1996, Mr. Legorreta was an investment banker at Lazard Frères in Paris and New York. Mr. Legorreta is also a co-founder of Pharmakon Advisors, a leading provider of debt capital to the life sciences industry.

Mr. Legorreta serves on the Board of Governors of the New York Academy of Sciences, as well as the Boards of Trustees of Rockefeller University, Brown University, the Hospital for Special Surgery, Pasteur Foundation (the U.S. affiliate of the French Institute Pasteur), Open Medical Institute and Park Avenue Armory.

Mr. Legorreta is the founder and chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities. Since its foundation in 2010 AMSA has provided over 450 scholarships to Mexican and Latin American doctors and healthcare providers to study abroad. Mr. Legorreta has a degree in industrial engineering from Universidad Iberoamericana in Mexico City.

Susannah Gray

Susannah Gray

Executive Vice President, Finance & Strategy

Ms. Gray has led the finance, treasury and accounting function at Royalty Pharma for over 10 years. Prior to joining Royalty Pharma in 2005, Ms. Gray was an investment banker and analyst at Chase Securities, Merrill Lynch, Bank of America, and CIBC World Markets. Ms. Gray has a BA from Wesleyan University and an MBA from Columbia University.

Jim Reddoch

Jim Reddoch, PhD

Executive Vice President, Head of Research and Investments

Dr. Reddoch has led the team at Royalty Pharma that focuses on sourcing and analyzing new investment opportunities and partnerships for over 10 years. Prior to joining Royalty Pharma in 2008, Dr. Reddoch was Head of Healthcare Research at FBR Capital Markets. Previously, Dr. Reddoch was a biotechnology analyst at Bank of America and CIBC World Markets. Dr. Reddoch serves on the board of Avillion, a London-based drug development company funded by Royalty Pharma and other investors, and on Memorial Sloan Kettering Cancer Center’s external review board for its Technology Development Fund. Dr. Reddoch has a BA from Furman University, a PhD in Biochemistry and Molecular Genetics from the University of Alabama, and was a postdoctoral fellow at Yale University.

George Lloyd

George Lloyd

Executive Vice President, Investments and General Counsel

Mr. Lloyd focuses on transaction structuring and execution and also leads the legal and compliance function at Royalty Pharma. Mr. Lloyd joined Royalty Pharma in 2011 after representing Royalty Pharma on all transactional work since 2006. Mr. Lloyd was previously a partner in Goodwin Procter’s Private Equity Group and an associate in Davis, Polk & Wardwell’s New York and Paris offices. Mr. Lloyd has an AB from Princeton University and a JD from New York University Law School.


Terrance Coyne

Chief Financial Officer

Mr. Coyne joined Royalty Pharma in 2010. Previously, Mr. Coyne was a biotechnology analyst at J.P. Morgan and Rodman & Renshaw, and began his career at Wyeth Pharmaceuticals. Mr. Coyne has a BS in business administration from La Salle University and an MBA from La Salle University.

“Our goal is to become the partner of choice for pharma and biotech companies, allowing them to focus their resources on strategic assets.”

Pablo Legorreta — Founder and Chief Executive Officer



Molly Chiaramonte, PhD

Senior Vice President, Research and Investments

Dr. Chiaramonte joined Royalty Pharma in 2008. Previously Dr. Chiaramonte was a biotechnology analyst at Jefferies & Company. Dr. Chiaramonte has a BA from Providence College, an MA in mathematics from the University of Colorado, a PhD in chemistry from the University of Colorado, and was a postdoctoral fellow at the University of Colorado Health Sciences Center.


Marshall Urist, MD, PhD

Senior Vice President, Research and Investments

Dr. Urist Joined Royalty Pharma in 2013. Previously, Dr. Urist was an executive director and the senior biotechnology analyst at Morgan Stanley. Dr. Urist has a BA, Phi Beta Kappa, from John Hopkins University, a PhD from Columbia University, and an MD from Columbia University.


Sara Klymkowsky

Vice President, Research and Investments

Ms. Klymkowsky joined Royalty Pharma in 2012. Previously, Ms. Klymkowsky was an analyst in the Healthcare Investment Banking group at Goldman Sachs & Co. Ms. Klymkowsky has a BSBA and BA in molecular, cellular and developmental biology from the University of Colorado at Boulder.


Brienne Kugler

Vice President, Research and Investments

Ms. Kugler joined Royalty Pharma in 2014. Previously, Ms. Kugler was a biotechnology equity research senior associate at Morgan Stanley. Ms. Kugler has a BS in materials science and engineering from Massachusetts Institute of Technology.


Volodymyr (Vlad) Nikolenko, PhD, MBA

Senior Associate, Research and Investments

Dr. Nikolenko joined Royalty Pharma in 2017. Previously, Dr. Nikolenko was an equity research associate on the Evercore ISI biotech and pharma team. Mr. Nikolenko also previously was a senior financial analyst at Merck and a senior portfolio analyst at Columbia Technology Ventures. Dr. Nikolenko has a BS/MS from Moscow Institute of Physics and Technology, an MBA from Columbia University, and a PhD in neuroscience from Columbia University.



Alexander von Perfall

Vice President, Investor Relations and Public Affairs

Mr. von Perfall joined Royalty Pharma in 2009. Previously, Mr. von Perfall was the co-founder and chief network officer of XTF, a start-up exchange traded fund ratings agency. Mr. von Perfall also previously worked for BMG Entertainment and Bertelsmann AG and the International Finance Corporation/World Bank Group. Mr. von Perfall serves on the boards of Lupus Therapeutics, a non-profit dedicated to accelerating the identification and development of new therapies to treat lupus and of the Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America. Mr. von Perfall has studied at the Hochschule St. Gallen in Switzerland, has a BA from the University of San Francisco, and an MBA from the Stern School of Business at New York University.


James S. Rielly

Senior Vice President, Finance

Mr. Rielly joined Royalty Pharma in 1999. Previously, Mr. Rielly was vice president of finance at Cadus Pharmaceutical Corporation. Mr. Rielly also previously was vice president of finance at Baring Brothers and Company Ltd. Mr. Rielly has a BSBA from Bucknell University and is a Certified Public Accountant.


Kristin Stafford

Chief Accounting Officer

Ms. Stafford joined Royalty Pharma in 2016. Previously, Ms. Stafford was a director at Ernst & Young LLP Capital Markets in London, specializing in US transactions involving European life sciences companies. Ms. Stafford also previously managed the external SEC reporting for iHeartMedia and was an auditor at Deloitte.  Ms. Stafford has a BA, with honors, from Sonoma State University.

Sarah Cata

Sarah Cata

Vice President, Finance

Ms. Cata joined Royalty Pharma in 2014. Previously, Ms. Cata was an associate in the Healthcare Investment Banking group at J.P. Morgan. Ms. Cata has a BA in Spanish and a BS in finance and accounting from Miami University.

Jessica Veeramachaneni

Jessica Veeramachaneni

Vice President & Controller

Ms. Veeramachaneni joined Royalty Pharma in 2011. Previously, Ms. Veeramachaneni was an auditor at PricewaterhouseCoopers. Ms. Veeramachaneni has a BBA in accounting and is a Certified Public Accountant.


Stephanie Ratner

Assistant Controller

Ms. Ratner joined Royalty Pharma in 2012. Previously, Ms. Ratner worked in forensic accounting. Ms. Ratner has a BS in accounting from Ramapo College of New Jersey and is a Certified Public Accountant.


Mina Fukuda

Tax Director

Ms. Fukuda joined Royalty Pharma in 2015. Previously, Ms. Fukuda was a Tax Manager at Ernst & Young LLP in the Wealth and Asset Management division, working for an array of asset management clients, specializing in hedge fund and private equity taxation. Ms. Fukuda has a BS, summa cum laude, in accounting from the University of Maryland and is a Certified Public Accountant.